Idelalisib‐rituximab induces durable remissions in TP53 disrupted B‐PLL but results in significant toxicity: updated results of the UK‐wide compassionate use programme

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2019-02, Vol.184 (4), p.667-671
Hauptverfasser:	Eyre, Toby A., Fox, Christopher P., Boden, Ali, Bloor, Adrian, Dungawalla, Moez, Shankara, Paneesha, Went, Richard, Schuh, Anna H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged B‐PLL Female Hematology Humans idelalisib Immunotherapy Leukemia, Prolymphocytic, B-Cell - drug therapy Leukemia, Prolymphocytic, B-Cell - genetics Leukemia, Prolymphocytic, B-Cell - mortality Male Middle Aged Monoclonal antibodies Mutation p53 Protein prolymphocytic leukaemia Purines - administration & dosage Purines - adverse effects Quinazolinones - administration & dosage Quinazolinones - adverse effects Remission Induction Rituximab Rituximab - administration & dosage Rituximab - adverse effects Toxicity TP53 deletion, TP53 Tumor Suppressor Protein p53 - genetics United Kingdom
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!